Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0035412 (
rhabdomyosarcoma
)
6,156
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
57Co-bleomycin appears to be one of the best tumor detecting agents at the moment. The localization within the cells is not yet known. This preclinical investigation had the aim to study the subcellular distribution of 57Co-bleomycin in liver, spleen and tumors of rats and mice. Mice with transplanted lymphosarcoma and osteosarcoma were used and rats with transplanted
rhabdomyosarcoma
. The concentration of 57Co-bleomycin was 2 to 10 times higher in the tumors as compared to the (normal) liver. This accumulation property was not found with the control substance: 57CoCl2. The highest radioactivity of 57Co-bleomycin (cpm/mg protein) was observed in subcellular fractions containing mitocohndria and lysosomes. After treatment of these fractions with hypertonic solutions it could be shown that enzymes of the mitochondrial matrix remained inside the vesicles under conditions of almost complete release of 57Co-bleomycin. Half of the lysosomal enzyme
acid phosphatase
was released too. From these experiments it is concluded that 57Co-bleomycin is preferentially localized in heavy secondary lysomes which are more fragile than the lighter lysosomes in the cells.
...
PMID:Subcellular localization of 57Co-bleomycin in normal and tumor tissues. 7 96
Acid phosphatase activity measured in a methylocholanthrene-induced murine
rhabdomyosarcoma
showed a monotonically increasing relation between enzyme activity and tumour volume. This could be related to the lytic activity of the enzyme in large tumours which become more hypoxic and necrotic, and hence enhance degradation and turnover of damaged tumour cells. The tumours were also subjected to irradiation using doses of 2.0, 3.8 and 6.0 Gy from a neutron therapy facility p(66MeV)/Be. The correlation between different doses and response of
acid phosphatase
activity could reflect the relation of magnitude of damage from metabolic disturbances, with dose. Furthermore exogenous ATP was shown to provide radioprotective action against neutron irradiation in two different experiments. The ATP reduced the activity of this lytic enzyme in irradiated tumours and also decreased tumour growth delay. This radioprotective role of exogenous ATP in a murine tumour could be related to physiological regulatory processes during defence mechanisms to maintain self-organisation in response to the radiation damage.
...
PMID:Acid phosphatase response in murine rhabdomyosarcoma for various tumour volumes and after different doses of neutron irradiation, alone or combined with exogenous ATP. 188 67